Fighting antibiotic resistance—strategies and (pre) clinical developments to find new antibacterials
S Walesch, J Birkelbach, G Jézéquel, FPJ Haeckl… - EMBO …, 2023 - embopress.org
Antibacterial resistance is one of the greatest threats to human health. The development of
new therapeutics against bacterial pathogens has slowed drastically since the approvals of …
new therapeutics against bacterial pathogens has slowed drastically since the approvals of …
[HTML][HTML] Antibiotics in the clinical pipeline as of December 2022
The need for new antibacterial drugs to treat the increasing global prevalence of drug-
resistant bacterial infections has clearly attracted global attention, with a range of existing …
resistant bacterial infections has clearly attracted global attention, with a range of existing …
[图书][B] 2019 antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline
World Health Organization - 2020 - books.google.com
Some rights reserved. This work is available under the Creative Commons Attribution-
NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https …
NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https …
Analysis of the clinical pipeline of treatments for drug-resistant bacterial infections: despite progress, more action is needed
MS Butler, V Gigante, H Sati, S Paulin… - Antimicrobial agents …, 2022 - Am Soc Microbiol
There is an urgent global need for new strategies and drugs to control and treat multidrug-
resistant bacterial infections. In 2017, the World Health Organization (WHO) released a list of …
resistant bacterial infections. In 2017, the World Health Organization (WHO) released a list of …
Antibiofilm activity of host defence peptides: complexity provides opportunities
Host defence peptides (HDPs) are integral components of innate immunity across all living
organisms. These peptides can exert direct antibacterial effects, targeting planktonic cells …
organisms. These peptides can exert direct antibacterial effects, targeting planktonic cells …
[HTML][HTML] Towards the sustainable discovery and development of new antibiotics
An ever-increasing demand for novel antimicrobials to treat life-threatening infections
caused by the global spread of multidrug-resistant bacterial pathogens stands in stark …
caused by the global spread of multidrug-resistant bacterial pathogens stands in stark …
The global preclinical antibacterial pipeline
U Theuretzbacher, K Outterson, A Engel… - Nature Reviews …, 2020 - nature.com
Antibacterial resistance is a great concern and requires global action. A critical question is
whether enough new antibacterial drugs are being discovered and developed. A review of …
whether enough new antibacterial drugs are being discovered and developed. A review of …
[HTML][HTML] 2021 antibacterial agents in clinical and preclinical development: an overview and analysis
World Health Organization - 2022 - books.google.com
Page 1 2021 ANTIBACTERIAL AGENTS IN CLINICAL AND PRECLINICAL DEVELOPMENT:
an overview and analysis World Health Organization Page 2 A PRE Page 3 2021 …
an overview and analysis World Health Organization Page 2 A PRE Page 3 2021 …
Antibiotic discovery and resistance: the chase and the race
The history of antimicrobial resistance (AMR) evolution and the diversity of the
environmental resistome indicate that AMR is an ancient natural phenomenon. Acquired …
environmental resistome indicate that AMR is an ancient natural phenomenon. Acquired …
Structure, assembly, and function of tripartite efflux and type 1 secretion systems in gram-negative bacteria
Tripartite efflux pumps and the related type 1 secretion systems (T1SSs) in Gram-negative
organisms are diverse in function, energization, and structural organization. They form …
organisms are diverse in function, energization, and structural organization. They form …